Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, and Cancer Treatment and Pharmacology.
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study
The SONIA trial shows the power and challenges of academic research
Improving communication between healthcare professionals and patients living with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 5)
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
The Lancet Breast Cancer Commission
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
Obesity-associated changes in molecular biology of primary breast cancer
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
EUSOMA quality indicators for non-metastatic breast cancer: An update
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
Changes over time in self-efficacy to cope with cancer and well-being in women with breast cancer: a cross-cultural study
Well‐being trajectories in breast cancer and their predictors: A machine‐learning approach
Aid of a machine learning algorithm can improve clinician predictions of patient quality of life during breast cancer treatments
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.